S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
NASDAQ:RXDX

Prometheus Biosciences (RXDX) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$199.60
$199.98
50-Day Range
$192.50
$199.92
52-Week Range
$23.27
$199.98
Volume
1.86 million shs
Average Volume
913,102 shs
Market Capitalization
$9.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$162.70

RXDX vs. ZLAB, ROIV, PEN, TFX, HSIC, CRL, QGEN, BIO, RGEN, and DVA

Should you be buying Prometheus Biosciences stock or one of its competitors? The main competitors of Prometheus Biosciences include Zai Lab (ZLAB), Roivant Sciences (ROIV), Penumbra (PEN), Teleflex (TFX), Henry Schein (HSIC), Charles River Laboratories International (CRL), Qiagen (QGEN), Bio-Rad Laboratories (BIO), Repligen (RGEN), and DaVita (DVA). These companies are all part of the "medical" sector.

Prometheus Biosciences vs.

Zai Lab (NASDAQ:ZLAB) and Prometheus Biosciences (NASDAQ:RXDX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment.

Zai Lab has a net margin of -156.07% compared to Zai Lab's net margin of -3,768.76%. Zai Lab's return on equity of -33.50% beat Prometheus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Zai Lab-156.07% -38.48% -32.78%
Prometheus Biosciences -3,768.76%-33.50%-29.59%

Prometheus Biosciences received 110 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 70.64% of users gave Prometheus Biosciences an outperform vote while only 62.50% of users gave Zai Lab an outperform vote.

CompanyUnderperformOutperform
Zai LabOutperform Votes
210
62.50%
Underperform Votes
126
37.50%
Prometheus BiosciencesOutperform Votes
320
70.64%
Underperform Votes
133
29.36%

Prometheus Biosciences has lower revenue, but higher earnings than Zai Lab. Prometheus Biosciences is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$251.80M9.20-$443.29M-$4.09-5.73
Prometheus Biosciences$6.81M1,403.55-$141.75M-$3.52-56.80

43.7% of Zai Lab shares are held by institutional investors. Comparatively, 92.7% of Prometheus Biosciences shares are held by institutional investors. 5.2% of Zai Lab shares are held by insiders. Comparatively, 3.4% of Prometheus Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Zai Lab presently has a consensus price target of $83.10, suggesting a potential upside of 259.74%. Prometheus Biosciences has a consensus price target of $162.70, suggesting a potential downside of 18.62%. Given Prometheus Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Zai Lab is more favorable than Prometheus Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zai Lab
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Prometheus Biosciences
0 Sell rating(s)
7 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.30

In the previous week, Zai Lab had 1 more articles in the media than Prometheus Biosciences. MarketBeat recorded 1 mentions for Zai Lab and 0 mentions for Prometheus Biosciences. Prometheus Biosciences' average media sentiment score of 1.87 beat Zai Lab's score of 0.77 indicating that Zai Lab is being referred to more favorably in the media.

Company Overall Sentiment
Zai Lab Very Positive
Prometheus Biosciences Positive

Zai Lab has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Prometheus Biosciences has a beta of -0.49, suggesting that its share price is 149% less volatile than the S&P 500.

Summary

Zai Lab beats Prometheus Biosciences on 9 of the 17 factors compared between the two stocks.


Get Prometheus Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXDX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RXDX vs. The Competition

MetricPrometheus BiosciencesBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$9.56B$235.90M$4.42B$6.20B
Dividend YieldN/A2.93%5.86%7.83%
P/E Ratio-56.80297.26121.3111.96
Price / Sales1,403.5520,399.622,883.2766.39
Price / CashN/A11.0921.3922.77
Price / Book12.404.543.824.56
Net Income-$141.75M-$34.56M$121.29M$181.66M

Prometheus Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZLAB
Zai Lab
1.921 of 5 stars
$24.92
+0.4%
$83.10
+233.5%
-30.3%$2.46B$215.04M-6.092,036Gap Down
ROIV
Roivant Sciences
2.194 of 5 stars
$12.41
+21.5%
$14.75
+18.9%
+226.6%$9.58B$61.28M-9.26904Insider Selling
Short Interest ↓
News Coverage
Gap Up
High Trading Volume
PEN
Penumbra
2.7285 of 5 stars
$245.61
-0.6%
$324.38
+32.1%
+25.7%$9.44B$847.13M331.913,900Analyst Report
Positive News
TFX
Teleflex
2.7333 of 5 stars
$199.94
-1.7%
$268.92
+34.5%
-2.8%$9.40B$2.90B25.6715,500News Coverage
Positive News
HSIC
Henry Schein
2.3433 of 5 stars
$74.52
+1.0%
$84.00
+12.7%
+11.4%$9.73B$12.65B21.9222,000Short Interest ↑
CRL
Charles River Laboratories International
2.8459 of 5 stars
$194.44
-1.6%
$237.09
+21.9%
-1.7%$9.97B$3.98B20.6221,400Short Interest ↑
QGEN
Qiagen
2.6789 of 5 stars
$39.61
+1.2%
$49.50
+25.0%
-3.1%$9.03B$2.14B26.956,178Short Interest ↓
BIO
Bio-Rad Laboratories
2.7586 of 5 stars
$350.25
-0.8%
$533.00
+52.2%
-15.7%$10.18B$2.77B-23.338,200Short Interest ↓
RGEN
Repligen
2.6195 of 5 stars
$158.68
-0.2%
$199.00
+25.4%
-17.2%$8.85B$801.54M65.572,025Positive News
DVA
DaVita
2.2964 of 5 stars
$95.71
-2.9%
$105.29
+10.0%
+14.9%$8.74B$11.61B19.0370,000Short Interest ↑

Related Companies and Tools

This page (NASDAQ:RXDX) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -